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Malaria-associated acute respiratory distress syndrome (MA-ARDS) is an often lethal 
complication of malaria. Currently, no adequate therapy for this syndrome exists. 
Although glucocorticoids (GCs) have been used to improve clinical outcome of ARDS, 
their therapeutic benefits remain unclear. We previously developed a mouse model of 
MA-ARDS, in which dexamethasone treatment revealed GC resistance. In the present 
study, we investigated GC sensitivity of mouse microvascular lung endothelial cells 
stimulated with interferon-γ (IFN-γ) and Plasmodium berghei NK65 (PbNK65). Upon 
challenge with IFN-γ alone, dexamethasone inhibited the expression of CCL5 (RANTES) 
by 90% and both CCL2 (MCP-1) and CXCL10 (IP-10) by 50%. Accordingly, whole 
transcriptome analysis revealed that dexamethasone differentially affected several gene 
clusters and in particular inhibited a large cluster of IFN-γ-induced genes, including 
chemokines. In contrast, combined stimulation with IFN-γ and PbNK65 extract impaired 
inhibitory actions of GCs on chemokine release, without affecting the capacity of the 
GC receptor to accumulate in the nucleus. Subsequently, we investigated the effects 
of GCs on two signaling pathways activated by IFN-γ. Dexamethasone left phosphor-
ylation and protein levels of signal transducer and  activator of transcription 1 (STAT1) 
unhampered. In contrast, dexamethasone inhibited the IFN-γ-induced activation of two 
mitogen-activated protein kinases (MAPK), JNK, and p38. However, PbNK65 extract 
abolished the inhibitory effects of GCs on MAPK signaling, inducing GC resistance. 
These data provide novel insights into the mechanisms of GC actions in endothelial 
cells and show how malaria may impair the beneficial effects of GCs.
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1. inTrODUcTiOn
Malaria remains a life-threatening disease with negative impact 
on social and political stability. More than 200 million clinical 
cases and around 400,000 deaths are reported annually (WHO 
website). Most malaria infections are uncomplicated but 
various complications including cerebral malaria (CM), severe 
malarial anemia, and malaria-associated acute respiratory 
distress syndrome (MA-ARDS) cause the majority of deaths 
(1, 2). MA-ARDS, which occurs in adults, constitutes an 
important but insufficiently studied complication of malaria 
(3, 4). MA-ARDS is characterized by lung edema and impaired 
gas exchange (2). Parasite-infected erythrocytes adhere to the 
endothelium (parasite sequestration) in the lungs and this trig-
gers leukocyte infiltration and proinflammatory cytokine pro-
duction (2, 3). Endothelial cells are activated by these cytokines 
and are likely the first cells altered in the lungs during ARDS 
(5). Also, parasite products such as hemozoin and histidine-
rich protein II have been shown to activate endothelium and 
increase endothelial barrier permeability (6, 7). Increased 
permeability of the microvascular barrier is typical in acute 
inflammation and plays a central role in the pathogenesis of 
ARDS (5, 8, 9). Moreover, this increased permeability results in 
interstitial edema and facilitates leukocyte infiltration. Immune 
cells play a crucial role in the development of MA-ARDS. 
Abundant monocyte and macrophage infiltrates both inside 
the blood capillaries and in the interstitium are found in post-
mortem histological sections of patients with MA-ARDS (10). 
Furthermore, lymphocytes and a small number of neutrophils 
are present (11). In murine MA-ARDS, especially CD8+ T cells 
are pathogenic (9). Recent studies also suggested neu trophils 
to play a detrimental role, whereas monocytes appeared rather 
protective by phagocytosing infected erythrocytes (12, 13). 
Currently, adequate treatment for MA-ARDS is not available 
(2, 9).
Glucocorticoids (GCs) are among the most effective therapy 
prescribed for various inflammatory diseases including asthma, 
allergy, and rheumatoid arthritis (14–16). GCs exert their anti-
inflammatory and immunosuppressive effects mainly via the 
glucocorticoid receptor (GR) which belongs to the superfamily 
of ligand-inducible transcription factors (17). Activated GR can 
bind to specific DNA motifs (glucocorticoid response elements, 
GREs) and transactivate gene transcription. GR interacts with 
DNA as dimers or monomers. Endogenous GCs favor monomeric 
GR interactions with half-site motifs. GR monomers bound to 
half sites in liver and macrophages induce transcription and 
determine tissue-specific actions of GR. In contrast, exogenous 
GCs regulate gene expression via GR homodimers binding to 
classic palindromic motifs (18). Moreover, GCs can inhibit gene 
transcription via another mechanism called transrepression, 
which largely depends on protein–protein interactions (19–22). 
Transrepression represents the main mechanism by which GCs 
inhibit proinflammatory transcription factors such as NF-κB 
and AP-1 (23).
Since macrophages, monocytes, epithelial cells, and endothe-
lial cells play different roles in the pathogenesis of ARDS, 
it is crucial to define the cell-specific mode of GC actions. In 
particular, recent reports suggest that macrophages are indis-
pensable for initiation and termination and of lung inflamma-
tion. Moreover, these cells initiate the repair process (24). For 
example, Vettorazzi et  al. showed that macrophages play an 
important role in the resolution of lung inflammation in animal 
models of acute lung injury. In macrophages, GCs synergize 
with proinflammatory stimuli to upregulate sphingosine kinase 
1 (SphK1) and its enzymatic product, sphingosine 1-phosphate 
(S1P)—the major regulators of endothelial barrier integrity in 
the lungs (25). Furthermore, anti-inflammatory actions of GCs 
in the lungs depend on the circadian system (26). GCs also exert 
essential effects on endothelial cells by regulating multiple pro-
cesses such as cytokine and chemokine expression and barrier 
permeability (27).
Although GCs remain an efficient therapy for inflammatory 
diseases, a subset of patients show poor or no response to GC 
therapy (15). GC resistance remains one of the major drawbacks 
of GC treatment and has been observed in patients suffering 
from diseases such as asthma, chronic obstructive pulmonary 
disease, and leukemia, and in various immune cells including 
peripheral blood mononuclear cells (PBMCs), B  cells, and 
alveolar macrophages (14, 28). A variety of molecular mecha-
nisms leads to GC resistance, e.g., increased GRβ expression, 
reduced GR translocation and impaired transactivation (29–31). 
Moreover, recent studies have confirmed that the endothelium 
represents an important target for GCs and several mechanisms 
of GC resistance in endothelial cells, including proteasomal 
degradation and epigenetic modifi cations of GR were reported 
(27, 32, 33).
We previously developed an in  vivo model of MA-ARDS 
using C57BL/6 mice infected with Plasmodium berghei NK65 
(PbNK65) (9). These mice develop MA-ARDS with increased 
vascular permeability, protein-rich lung edema, and leukocyte 
infiltration. According to the observed histopathology, this 
mouse model exhibits important similarities to the human 
MA-ARDS and is suitable to investigate both pathogenesis and 
therapeutic strategies (2). High doses of GCs failed to inhibit 
expression of several proinflammatory cytokines in the lungs 
of these mice suggesting that malaria decreases GC sensitivity 
(9). GC resistance may also explain why clinical trials against 
cerebral malaria with dexamethasone were unsuccessful (34, 35). 
The mechanisms underlying GC resistance in this model of 
MA-ARDS remain unknown. In this study, we established 
an in  vitro model of MA-ARDS with L2 microvascular lung 
endothelial cells and we aimed to delineate mechanisms of GC 
resistance in MA-ARDS.
2. MaTerials anD MeThODs
2.1. cell cultures
The murine lung microvascular endothelial cell line (L2 
M VEC) was cultured in RPMI medium (Gibco, Belgium) 
supplemented with 2  mM l-glutamine (Gibco), 0.1  mg/mL 
streptomycin (Sigma, Belgium), 200  U/mL penicillin (Kela, 
Belgium), and 10% FCS (Gibco). Cells were grown in 5% CO2  
at 37°C.
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2.2. Mice
All animal experiments were performed in accordance to the 
regulations as declared in Directive 2010/63/EU from the 
European Union and the Belgian Royal Decree of May 29, 2013, 
and were approved by the Animal Ethics Committee from the 
KU Leuven (project number P163-2014, License LA1210186, 
Belgium). All efforts were made to minimize suffering of 
animals. Unless otherwise indicated, male Balb/c mice were 
obtained from Janvier (7–8  weeks old, Le Genest-Saint-Isle, 
France). Mice were injected intraperitoneally with 106 PbNK65-
infected red blood cells (a kind gift of the late Prof. D. Walliker, 
University of Edinburgh). Mice were kept in a conventional ani-
mal house and drinking water was supplemented with 4-amino 
benzoic acid (0.375  mg/mL, PABA, Sigma-Aldrich, Bornem, 
Belgium). Parasitemia was determined by microscopic analysis 
of tail blood smears after Giemsa staining (1/10 dilution, VWR, 
Heverlee, Belgium). Mice were sacrificed 8  days after infec-
tion (when parasitemia was approximately 4%) by euthanasia 
with Dolethal (Vtoquinol, Aartselaar, Belgium; 200  mg/mL, 
intraperitoneal injection of 50 µL) and cardiac punctures were 
performed.
2.3. Ex Vivo cultivation of PbnK65  
and extract Production
After cardiac punctures, blood was filtered with Plasmodipur 
filters (Europroxima) to remove leukocytes and washed with 
RPMI medium (Gibco) supplemented with 25  mM HEPES, 
0.425  g NaHCO3, 2  mM l-glutamine (Gibco), 5  mM glucose 
(Sigma), and 20% FCS. The pellet was resuspended and seeded 
into culture flasks. Cells were gassed with a mixture of 92.5% N2, 
5.5% CO2, 2% O2 and cultured overnight at 37°C. The next day 
the cultures were centrifuged, resuspended in RPMI medium 
and loaded on MACS columns (Miltenyi Biotec, NL) to purify 
the schizonts. After elution the schizonts were diluted to the con-
centration of 108/mL in RPMI medium, aliquoted, and frozen 
at −20°C. Next they were thawed and frozen at −20°C again to 
produce the extract.
2.4. stimulation of l2 MVec cells with 
iFn-γ, PbnK65 extract, and  
MaPK inhibitors
L2 MVECs were seeded in 6-, 24-, 48-, or 96-well plates at the 
concentration of 5 × 104 cells/mL. After expanding the cells for 
24  h, they were washed with medium and stimulated for 24  h 
with combinations of murine IFN-γ (20  ng/mL, PeproTech, 
USA), parasite extract (107 infected red blood cells—iRBCs/mL), 
murine red blood cells extract (107 RBCs/mL), and dexametha-
sone (100 nM dissolved in DMSO, Sigma). JNK, p38, and ERK 
inhibitors (SP600125, SB203580, and FR180204, dissolved in 
DMSO, R&D, UK) were used at 20, 5, and 10 µM, respectively. 
After stimulation, plates were centrifuged (5 min, 1,200 rpm, RT) 
and supernatants were collected for ELISA and stored at −20°C. 
Cytokines were analyzed by ELISA (R&D). Cells were washed 
with PBS, lysed with RLT buffer with β-mercaptoethanol from 
RNeasy Mini kit (Qiagen, Belgium), and stored at −80°C for RNA 
extraction.
2.5. Quantitative rT-Pcr and rna-seq
RNA was extracted with RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer’s protocol. RNA concentration and 
purity were evaluated with Nanodrop 1000 (Thermo Scientific, 
Belgium). RNA (0.25 µg) was converted to cDNA using high-
capacity cDNA reverse transcription kit (Applied Biosystems). 
Quantitative RT-PCR was performed with 6.25 or 0.125  ng 
cDNA using predesigned primers (IDT) and TaqMan Universal 
PCR Master Mix (Applied Biosystems), respectively. RNA-Seq 
expression profiling was performed by the Genomics Core UZ 
Leuven. Per independent experiment RNA from three technical 
replicates per experimental condition was pooled and 3 µg RNA/
experimental condition were sequenced from a total of three 
independent experiments. Illumina TruSeq stranded mRNA kit 
was used and the single-end sequencing was performed. 33 M 
50 bp reads per sample were sequenced. Reads were aligned to 
mm10 murine genome using TopHat. A heatmap with highly 
variable genes across the samples was plotted using pheatmap 
package (pheatmap). The rlog transformed counts of each gene 
were centered across the samples. Ribosomal RNA genes and 
predicted genes that were increased in one sample (GC027190) 
were excluded from the rlog data used for heatmap since this 
increase was a result of an imperfect poly-A selection during 
the library preparation of this sample. Differential expression 
analysis was performed with DESeq2 (36). Differences in 
gene expression with a FDR adjusted p value below 0.1 were 
considered significant. Gene ontology analysis of differentially 
expressed genes was performed with clusterProfiler package 
(37). Motif analysis of the proximal promoter region (400  bp 
upstream of the transcription start site till 100 bp downstream) 
was performed using Homer software (Homer motif analysis). 
RNA-seq data were submitted to ArrayExpress (accession 
 number E-MTAB-5921 (ArrayExpress URL)).
2.6. Western Blot
For Western blot analysis, protein extracts from L2 MVECs 
stimulated with IFN-γ, PbNK65 extract, IFN-γ and PbNK65 
extract in the presence or absence of dexamethasone were sepa-
rated on SDS PAGE gels and blotted onto a PVDF membrane. 
Blocking was performed with BSA (Carl Roth Gmbh, Belgium) 
or non-fat dry milk (Bio Rad, USA). The following specific 
primary Abs were used: JNK, pJNK, p38, p-p38 (1:2,000, Cell 
Signaling Technology, The Netherlands), p-GR S211 (1:1,000, 
Cell Signaling Technology), p-GR S226 (1:1,000, Abcam), GR 
H300 (1:1,000, Santa Cruz, Germany), p-STAT1 Tyr701 (1:1,500, 
Cell Signaling Technology), and STAT1 (1:5,000, Cell Signaling 
Technology). Fusion solo S system (Vilber, France) was used to 
take chemiluminescence Western blot images. Quantification of 
Western blot images was performed by densitometry (ImageJ 
software was used).
2.7. gr nuclear Translocation
Cells were seeded on coverslips and incubated in phenol-red-free 
and serum-free medium for 4  h. Cell fixation, methanol per-
meabilization, and staining were performed according to Cell 
Signaling guidelines. GR was visualized with the GR polyclonal 
FigUre 1 | Dexamethasone inhibits proinflammatory cytokine secretion in lung endothelium stimulated with IFN-γ. L2 MVECs were treated with vehicle (con) or 
IFN-γ (20 ng/mL) in the presence or absence of dexamethasone (Dex, 100 nM) for 24 h. CCL2 (MCP-1), CXCL10 (IP-10), and CCL5 (RANTES) expression levels 
were analyzed by ELISA (a) and real-time qPCR (B). Statistical significance was evaluated using ANOVA (***p < 0.001). Data show combined results from three 
independent experiments.
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(H300) antibody (Santa Cruz, Germany), used at 1:200, followed 
by probing with Alexa Fluor 488 (Invitrogen, Belgium). Nuclei 
were visualized using 4′,6-diamidino-2-phenylindole (DAPI) 
staining. A motorized inverted IX81 FluoView FV1000 laser 
scanning confocal microscope (Olympus) was used to record 
high-resolution images. Assessment of intracellular localization 
of protein signal was done double blind.
2.8. statistical analysis
Statistical analysis was performed with R (The R Project for 
Statistical Computing). Mann–Whitney or ANOVA was used to 
analyze ELISA and qPCR data. Statistical significance was set at 
a p value below 0.05.
3. resUlTs
3.1. lung endothelial cells remain gc 
sensitive upon stimulation with iFn-γ
IFN-γ plays a crucial role in the induction of chemokines in mouse 
models of complicated malaria (38, 39). To evaluate whether 
IFN-γ might cause GC resistance in lung endothelial cells, we 
stimulated L2 MVECs with IFN-γ in the presence or absence of 
dexamethasone for 24 h. IFN-γ induced CC chemokine ligand 
2 (CCL2, also known as monocyte chemoattractant protein 1 
or MCP-1), CXC chemokine ligand 10 (CXCL10, also known as 
IFN-γ-induced protein 10 or IP-10), and CCL5 (also known as 
regulated on activation normal T cell expressed and secreted or 
RANTES) on both protein and RNA levels (Figure 1). CXCL10 
(IP-10) showed the strongest induction. Dexamethasone inhib-
ited IFN-γ-induced chemokine secretion, suppressing CCL5 
(RANTES) by 90% and both CXCL10 (IP-10) and CCL2 (MCP-1) 
approximately by 50% (Figure 1A). Real-time qPCR experiments 
revealed 90% inhibition of CCL5 (RANTES) and 71% inhibition 
of both CXCL10 (IP-10) and CCL2 (MCP-1). Moreover, treat-
ment with dexamethasone (with or without IFN-γ) induced 
DUSP-1 (MKP1), GILZ (TSC22d3), and FKBP51 (Figure S1 
in Supplementary Material), indicating that IFN-γ did not 
alter GC-mediated transactivation of these genes. These results 
indicate that IFN-γ-stimulated lung endothelial cells remain GC 
sensitive.
3.2. gcs Differentially affect the 
Transcriptional response to iFn-γ  
in lung endothelial cells
To further characterize the transcriptional targets indicating GC 
sensitivity in lung endothelial cells, we analyzed by RNA-Seq 
A B
D E
C
FigUre 2 | GCs diminish transcriptional activity induced by IFN-γ. Genome wide expression was measured (n = 3), log2FoldChange has been depicted  
including standard error estimate (lfcSE, error bars). (a) Top 30 genes activated by IFN-γ in endothelial cells. (B) Top 30 genes downregulated by dexamethasone  
in endothelial cells stimulated with IFN-γ. (c) Top 30 genes induced by dexamethasone in IFN-γ-stimulated endothelial cells. (D) Venn diagram depicts overlap 
between genes induced by IFN-γ and repressed by dexamethasone. (e) Biological process GO analysis (top 30 terms) of genes induced at least twofold by IFN-γ 
and repressed at least 50% by dexamethasone.
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the transcriptome of L2 MVECs stimulated with IFN-γ in the 
 presence or absence of dexamethasone. IFN-γ induced expres-
sion of various guanylate binding proteins (GBPs, Figure  2A), 
which trigger antimicrobial effector mechanisms via inhibition 
of replication of intracellular pathogens (40). Similarly, we 
found several interferon-induced proteins with tetratricopeptide 
repeats (IFITs, Supplementary File 1). These proteins inhibit 
viral replication (41). IFN-γ also increased expression of H-2 
class II histocompatibility genes and adhesion molecules such 
as vascular cell adhesion protein 1 (VCAM-1) and intercellular 
adhesion molecule 1 (ICAM-1, Supplementary Files 1 and 2). 
Moreover, IFN-γ potently induced transcription of various 
TaBle 1 | Differentially expressed chemokines and cytokines in lung endothelial 
cells stimulated with IFN-γ in the presence or absence of dexamethasone.
gene symbol iFn-γ vs. con 
(log2Fc)
iFn-γ + Dex vs. iFn-γ 
(log2Fc)
CXCL16 2.4 −1.2
CXCL14 −1.7 0.75
CXCL12 −0.8 1.2
CXCL11 7.5 −2.6
CXCL10 7.4 −1.6
CXCL9 9.7 −1.6
CXCL5 NS −1.4
CXCL1 NS −1.2
CCL27a 0.8 NS
CCL22 3.9 −2
CCL20 1.4 −1.5
CCL17 NS −1
CCL12 3.8 −1.4
CCL11 1.9 NS
CCL9 −1.3 0.9
CCL8 3.3 −0.9
CCL7 1.6 −1.4
CCL6 1.2 NS
CCL5 6 −3.1
CCL4 2.4 −2.2 
CCL3 1.1 −2.2 
CCL2 2.2 −1.6 
IL-34 NS −1.1 
IL-33 −1.5 NS 
IL-27 3.4 −1.8 
IL-18 0.6 0.6 
IL-15 2.4 −0.5 
IL-10 1.4 1.4 
IL-7 1.2 NS 
IL-6 0.8 −1.6 
IL-1α 2.5 −1.6 
IL-1β 4.2 −2.5 
TNF 2.2 −1.6 
TNFSF18 1 NS 
TNFSF15 2.1 −1.6 
TNFSF13b 2.8 NS 
TNFSF11 −0.8 NS 
TNFSF8 −1.3 NS 
FC, fold change; NS, non-significant.
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proinflammatory CXC and CCL chemokines including CXCL9 
(also known as monokine induced by gamma interferon or 
MIG), CXCL11 (also known as Interferon-inducible T cell alpha 
chemoattractant or I-TAC), CXCL10 (IP-10), CCL5 (RANTES), 
and CCL2 (MCP-1, Figure 2A; Table 1; Supplementary Files 1). 
These data on chemokine induction further confirm the ELISA 
and qRT-PCR experiments shown in Figure 1.
Dexamethasone significantly inhibited large clusters of 
IFN-γ-induced genes, which included several CXC and CCL 
chemokines (Table  1; Supplementary Files 1 and 3). In par-
ticular, dexamethasone markedly diminished transcription of 
CCL5 (RANTES, more than 85% reduction), CXCL11 (I-TAC, 
more than 80% reduction), CCL4, and CCL3 (more than 75% 
reduction, Figure 2B). Also, IFN-γ-induced interleukin 1β (IL-
1β), IL-27, and IFITs were downregulated by dexamethasone. In 
contrast, the expression of GBPs, signal transducer and activa-
tor of transcription (STAT) family members, and the cytokine 
IL-15 was resistant to GC-mediated transcriptional inhibition 
(Supplementary File 1).
In addition, we found a large cluster of genes upregulated by 
GCs (Supplementary File 1). Dexamethasone induced several 
anti-inflammatory genes in IFN-γ-stimulated endothelial cells 
including orosomucoid-1 (Orm1, Fold Change 11.3), DEP 
domain-containing mTOR-interacting protein (DEPTOR, Fold 
Change 5.3), and TSC22 domain family, member 3 (TSC22d3 
also known as GILZ, Fold Change 4.6, Figure 2C)—a known GR 
target gene. These genes were also upregulated upon treatment 
with dexamethasone alone (Supplementary File 4). Interestingly, 
another set of genes was repressed by IFN-γ alone, but the 
expression was restored when dexamethasone was added. These 
genes include CXCL12, Angptl7, TGF-β2, TLR7, and TNFRSf21 
(Supplementary File 1). Altogether, these data indicate that 
lung endothelial cells are GC sensitive, when stimulated with 
IFN-γ. Furthermore, these cells provide a novel model to study 
GR-dependent responses.
As for the affected pathways, gene ontology (GO) analysis of 
genes induced by IFN-γ at least 2-fold and inhibited by dexa-
methasone at least by 50% (Figure  2D; Supplementary File  5) 
revealed a high prevalence of biological process GO terms 
related to regulation of immune response and proinflammatory 
signaling pathways such as MAPK (Figure 2E). Several binding 
partners have been involved in GR-mediated repression of pro-
inflammatory genes including AP-1, NF-κB, and IRF3 (42–44). 
Interestingly, a computational analysis of the 400-bp region 
upstream of genes induced by IFN-γ at least 2-fold and inhibited 
by dexamethasone at least by 50% showed a significant enrich-
ment of the binding sites for IRF and NF-κB families but not for 
GR (Table S1 in Supplementary Material). These results remain in 
line with previous findings since in LPS-stimulated macrophages, 
less than 6% of GR binding sites occurred at proximal promoter 
regions (44). Also, GR can tether to DNA-bound TFs such as 
NF-κB without requiring a GRE motif.
3.3. PbnK65 extract in combination  
with iFn-γ induces gc resistance  
in lung endothelial cells
Although GC resistance has been observed in our murine 
model of MA-ARDS (9), the above results indicate that IFN-γ- 
stimulated lung endothelial cells remain GC sensitive. As seques-
tering parasites release a variety of products which can further 
activate endothelial cells (6, 7), we investigated whether addition 
of parasite extract might alter the GC sensitivity of L2 MVECs. 
PbNK65 extract in combination with IFN-γ increased the mRNA 
levels of CCL2 (MCP-1) and CCL5 (RANTES), respectively, 2-fold 
and 3-fold in comparison to IFN-γ alone (Figure 3A). PbNK65 
alone increased only CCL2 (MCP-1) protein levels and interest-
ingly, this induction was sensitive to dexamethasone (Figure 3B). 
Importantly, dexamethasone failed to inhibit mRNA and protein 
induction of CCL2 (MCP-1), CCL5 (RANTES), and CXCL10 
(IP-10), when cells were challenged with the combination of 
PbNK65 extract and IFN-γ (Figures 3A,B). These results indi-
cate that PbNK65 extract impairs GC-mediated transrepression 
of these inflammatory chemokines observed after stimulation 
FigUre 3 | PbNK65 extract in combination with IFN-γ induces GC resistance in lung endothelial cells. L2 MVECs were treated with vehicle (con), IFN-γ (20 ng/mL), 
PbNK65 extract or IFN-γ and PbNK65 extract (PbNK65, 107 infected RBCs/mL) in the presence or absence of dexamethasone (Dex, 100 nM) for 24 h. CCL2 
(MCP-1), CXCL10 (IP-10), and CCL5 (RANTES) levels were analyzed by real-time qPCR (a) and ELISA (B). Statistical significance was evaluated using Mann–
Whitney test (**p < 0.01, ***p < 0.001). Data represent combined results from at least two independent experiments.
7
Zielin´ska et al. Malaria Induces Glucocorticoid Resistance
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1199
with IFN-γ alone. In contrast, PbNK65 extract did not decrease 
GC-induced transactivation of DUSP-1 (MKP1), GILZ 
(TSC22d3), and FKBP51 (Figure S1 in Supplementary Material).
To evaluate the time course of the development of GC resist-
ance, we stimulated lung endothelial cells with PbNK65 extract 
and IFN-γ for 6, 24, and 48  h in the presence or absence of 
dexamethasone and analyzed CCL2 (MCP-1) and CXCL10 (IP-
10) secretion. After 6 h, chemokine levels remained low both in 
the resistant condition with PbNK65 extract and IFN-γ and in 
the sensitive one with IFN-γ alone (Figure S2 in Supplementary 
Material). GC resistance for CCL2 (MCP-1) occurred following 
24-h stimulation with PbNK65 extract and IFN-γ and was still 
present after 48  h (Figure S2A in Supplementary Material). 
PbNK65 extract and IFN-γ induced GC resistance for CXCL10 
(IP-10) already after 6 h (Figure S2B in Supplementary Material). 
Notwithstanding these gene-specific differences in kinetics, all 
studied genes underwent GC resistance upon combining IFN-γ 
with PbNK56 extract. In contrast, upon stimulation with IFN-γ 
alone endothelial cells remained fully GC sensitive even after 48 h 
(Figures S2C,D in Supplementary Material).
As a control for the PbNK65 extract, we stimulated lung 
endothelial cells with extract from non-infected red blood 
FigUre 4 | Murine red blood cell extract (RBC) exhibits no effect on cytokine induction and GC sensitivity of lung endothelial cells. L2 MVECs were stimulated with 
vehicle (con), IFN-γ (20 ng/mL), RBC (107 RBCs/mL), RBC and IFN-γ in the presence or absence of dexamethasone (Dex, 100 nM) for 24 h. CCL2 (MCP-1) and 
CXCL10 (IP-10) production was analyzed by ELISA. Statistical significance was evaluated using ANOVA (***p < 0.001). Data represent combined results from 2 
independent experiments.
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cells (RBC) and evaluated GC sensitivity. RBC extract did not 
induce CCL2 (MCP-1) or CXCL10 (IP-10) in endothelial cells 
(Figure 4). When combined with IFN-γ, RBC extract failed to 
enhance secretion of proinflammatory chemokines. Furthermore, 
dexamethasone inhibited CCL2 (MCP-1) and CXCL10 (IP-10) 
production induced by IFN-γ in the presence of RBC extract, 
showing that RBC extract is not able to induce GC resistance. 
These results confirm that parasite components but not RBC 
components mediate GC resistance.
3.4. PbnK65/iFn-γ cotreatment Preserves 
homologous gr Downregulation and gr 
nuclear Translocation
GR undergoes homologous downregulation when incubated 
with its ligand for longer periods of time. Perturbations of 
this process may be lead to GC resistance (45, 46). To evalu-
ate the levels of GR, we stimulated L2 MVECs for 6 or 24  h 
with vehicle (DMSO), red blood cell extract (RBC), IFN-γ, 
PbNK65 extract, IFN-γ and PbNK65 extract in the presence 
or absence of dexamethasone. The levels of GR remained 
unchanged in the resistant condition with IFN-γ and PbNK65 
extract when compared to the sensitive condition with IFN-γ 
alone. Additionally, the capacity and extent of GC-induced GR 
homologous downregulation remained unaffected in either 
the sensitive or resistant condition. We also investigated the 
serine-211 (S211) phosphorylation of GR, since this modifica-
tion is associated with transcriptionally active GR and provides 
a means for cross-talk with other signaling pathways (47). 
As expected, dexamethasone alone induced S211 phospho-
rylation. Moreover, phosphorylation of GR at S211 remained 
present when cells were challenged with IFN-γ or IFN-γ with 
PbNK65 extract in the presence of dexamethasone (Figure 5A; 
Figure S3 in Supplementary Material). We also evaluated 
the GR S226 phosphorylation, which inhibits GR function 
(48, 49). Dexamethasone inhibited GR S226 phosphorylation 
upon stimulation with IFN-γ or IFN-γ with PbNK65 extract 
(Figure 5B). These data indicate that GC resistance following 
IFN-γ/PbNK65 cotreatment is most likely not caused by defec-
tive GR phosphorylation or GR homologous downregulation 
mechanisms.
Since impaired GR nuclear translocation leads to GC resist-
ance (31, 50), we assessed the ability of dexamethasone to 
induce GR translocation in lung endothelial cells. L2 MVECs 
were  challenged for 24  h with PbNK65 extract and IFN-γ and 
dexamethasone was added during the last hour of stimulation 
(Figure  6). Immunofluorescence microscopy revealed that in 
unstimulated cells GR localized mainly in the cytoplasm and 
translocated to the nucleus upon dexamethasone exposure. GR 
also translocated to the nucleus upon treatment with IFN-γ 
and dexamethasone. Furthermore, the translocation occurred 
in the GC resistant condition with PbNK65 extract and IFN-γ 
(Figure 6). We also obtained similar data for a shorter time point 
of 2 or with 24 h cotreatment with IFN-γ, PbNK65 extract and 
dexamethasone (Figures S4A,B in Supplementary Material). 
These data indicate that GC resistance is not caused by any defect 
in GR translocation.
3.5. Dexamethasone Fails to inhibit  
sTaT1 activation upon challenge with 
iFn-γ or PbnK65 extract and iFn-γ
Since IFN-γ signals via STAT1 to induce gene transcription, we 
evaluated the effect of dexamethasone on STAT1 activation in 
the GC sensitive condition with IFN-γ and in the resistant one 
with IFN-γ and PbNK65 extract. RNA-Seq data showed that 
dexamethasone failed to affect STAT1 expression induced by 
IFN-γ and this result was validated by qRT-PCR (Figure 7A). 
Since STAT1 phosphorylation at Tyr 701 controls STAT1 signal-
ing, we subsequently addressed the impact of dexamethasone on 
phosphorylated STAT1. We showed that STAT1 phosphoryla-
tion induced by IFN-γ remained unaffected by dexamethasone 
both in the GC sensitive (IFN-γ) and the GC resistant condition 
(IFN-γ and PbNK65 extract, Figure 7B).
FigUre 6 | IFN-γ and PbNK65 extract preserve GR nuclear translocation in 
lung endothelial cells. L2 MVECs were stimulated with solvent (con), IFN-γ 
(20 ng/mL) or IFN-γ and PbNK65 extract (107 infected RBCs/mL) for 24 h 
and treated for 1 h with dexamethasone (100 nM). Endogenous GR was 
visualized (green) through indirect immunofluorescence using anti-GR Ab. 
DAPI staining (blue) indicates the nuclei of the cells.
FigUre 5 | IFN-γ and PbNK65 extract do not interfere with either GR 
expression or GR phosphorylation. (a,B) Western blot analysis of lysates of 
L2 MVECs stimulated for 24 h with solvent (DMSO), red blood cells extract 
(RBC, 107 RBCs/mL), IFN-γ (20 ng/mL), PbNK65 extract  
(107 infected RBCs/mL), IFN-γ and PbNK65 extract in the presence or 
absence of dexamethasone (Dex, 100 nM).
9
Zielin´ska et al. Malaria Induces Glucocorticoid Resistance
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1199
activated by IFN-γ receptor signaling (51, 52). To address the 
role of specific members of the MAPK family in the induction of 
proinflammatory chemokines in our model, we used the JNK-, 
p38-, and ERK-specific inhibitors: SP600125, SB203580, and 
FR180204, respectively. Treatment with JNK and p38 inhibitors 
significantly reduced proinflammatory response induced by 
IFN-γ in lung endothelial cells. Inhibition of p38 reduced CCL2 
(MCP-1) levels by 28%, whereas inhibition of JNK blocked 
CXCL10 (IP-10), CCL2 (MCP-1), and CCL5 (RANTES) by 55, 
59, and 83%, respectively (Figure  8A). Accordingly, JNK and 
p38 inhibition blocked chemokine induction in the GC resist-
ant condition upon combining IFN-γ with PbNK65 extract. 
SB203580 inhibited CXCL10 (IP-10), CCL2 (MCP-1), and CCL5 
(RANTES) levels by 44, 49, and 54%, whereas SP600125 reduced 
CXCL10 (IP-10), CCL2 (MCP-1), and CCL5 (RANTES) by 69, 
79, and 94%, respectively (Figure 8B). Inhibition of ERK failed 
to reduce CXCL10 (IP-10) CCL2 (MCP-1) or CCL5 (RANTES) 
levels upon challenge with IFN-γ and PbNK65 extract (Figure S6 
in Supplementary Material).
Since previous studies indicated that GCs inhibit MAPK 
family members phosphorylation (53, 54), we investigated the 
effects of dexamethasone on p38 and JNK phosphorylation in 
endothelial cells stimulated with IFN-γ with and without PbNK65 
extract in the presence or absence of dexamethasone. We found 
that dexamethasone blocked p38 and JNK phosphorylation 
upon challenge with IFN-γ (Figures  9A,B). Quantification of 
the Western blot data revealed that, upon challenge with IFN-γ, 
dexamethasone reduced p38 and JNK phosphorylation on aver-
age by 69 and 61%. In unstimulated cells, dexamethasone also 
blocked p38 and JNK phosphorylation by 58 and 63%, respec-
tively (Figures 9C,D). In contrast, when IFN-γ was combined 
with PbNK65 extract dexamethasone failed to inhibit p38 and 
JNK phosphorylation by more than 14 and 4% (Figures 9A–D). 
These data suggest that dexamethasone inhibits IFN-γ-mediated 
induction of CXCL10 (IP-10), CCL2 (MCP-1), and CCL5 
(RANTES) at least in part by blocking the activation of p38 and 
JNK. Furthermore, this inhibitory mechanism is impaired in the 
GC resistant condition.
4. DiscUssiOn
In this study, we show that PbNK65 extract in combination 
with IFN-γ induces GC resistance in lung endothelial cells. GCs 
block JNK and p38 activation and proinflammatory chemokine 
release upon challenge with IFN-γ. However, stimulation with 
PbNK65 extract in combination with IFN-γ impairs the ability 
of GCs to block JNK and p38 signaling (Figure 10).
IFN-γ plays an important role in controlling both the liver and 
the blood stage of malaria. However, it can also aggravate malaria 
infections (38). For example, IFN-γ has been shown to exacerbate 
the pathology in animal models of cerebral malaria (38, 55). IFN-
γ synergizes with lymphotoxin-α and TNF to induce the expres-
sion of adhesion molecules (E-selectin and ICAM-1) (56). In line 
herewith, our RNA-Seq analysis in lung endothelial cells showed 
that IFN-γ induces transcription of vascular cell adhesion protein 
1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). 
Moreover, IFN-γ produced by CD4+ T cells upregulates CXCL9 
3.6. iFn-γ and PbnK65 extract impair 
gc-Mediated inhibition of MaPK signaling
MAPK family members play an important role in the generation 
and fine-tuning of inflammatory responses and are known to be 
FigUre 8 | p38 and JNK inhibitors impair proinflammatory cytokine expression in lung endothelial cells. L2 MVECs were stimulated with IFN-γ (20 ng/mL)  
(a) or IFN-γ (20 ng/mL) and PbNK65 extract (PbNK65, 107 infected RBCs/mL) (B) in the presence of JNK inhibitor SP600125 (SP, 20 µM) or p38 inhibitor 
SB203580 (SB, 5 µM) for 24 h. Protein levels of CXCL10 (IP-10), CCL2 (MCP-1), and CCL5 (RANTES) were determined by ELISA. Statistical significance  
was evaluated using ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001). Data represent combined results from three independent experiments.
FigUre 7 | Dexamethasone fails to inhibit STAT1 expression or STAT1 phosphorylation induced by IFN-γ or IFN-γ and PbNK65 extract. (a) L2 MVECs were 
stimulated with solvent (con) and IFN-γ (20 ng/mL) in the presence or absence of dexamethasone (Dex, 100 nM) for 24 h. STAT1 expression was analyzed 
by qRT-PCR. Statistical significance was evaluated using Mann-Whitney test. Data show combined results from three independent experiments. (B) Western 
blot analysis of lysates of L2 MVECs stimulated for 6 or 24 h with IFN-γ (20 ng/mL), PbNK65 extract (107 infected RBCs/mL), IFN-γ and PbNK65 extract in 
the presence or absence of dexamethasone (Dex, 100 nM) and red blood cell extract (RBC, 107 RBCs/mL) was performed using anti-STAT1 and anti-
pSTAT1 Ab.
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FigUre 9 | Dexamethasone fails to suppress JNK and p38 activation after challenge with IFN-γ and PbNK65 extract. Western blot analysis of L2 MVEC lysates 
stimulated for 24 h with IFN-γ (20 ng/mL), IFN-γ and PbNK65 (107 infected RBCs/mL) extract in the presence or absence of dexamethasone (Dex, 100 nM) was 
performed using anti-p-p38, anti-p38 (a), anti-pJNK, and anti-JNK (B) Ab. Data are representative of three independent experiments. (c,D) Data from three 
independent experiments were normalized against actin and percentage inhibition by dexamethasone was calculated.
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(MIG) and CXCL10 (IP-10) in endothelial cells and induces 
CD8+ T cell recruitment into the brain (39, 57). IFN-γ KO mice 
are protected from cerebral malaria and show lower leukocyte 
infiltration in the brain (58).
The involvement of IFN-γ in GC resistance has extensively 
been studied (59, 60). In the present study, we show that lung 
endothelial cells remain GC sensitive upon challenge with 
IFN-γ. However, combined treatment with IFN-γ and PbNK65 
extract impairs GC-mediated transcriptional inhibition of pro-
inflammatory cytokines. IFN-γ has been shown to induce GC 
resistance in other disease models in combination with bacte-
rial products or cytokines. For example, cooperative signaling 
between IFN-γ and LPS induces IL-27 in mouse macrophages 
and inhibits GR nuclear translocation (59). In airway smooth 
muscle cells, treatment with IFN-γ and TNF causes GC resist-
ance. Short-term stimulation with IFN-γ and TNF impairs 
GR binding to DNA and GRE-dependent transcription via 
upregulation of GR-β, whereas long-term treatment depletes 
GRIP-1 from the GR transcriptional regulatory complexes 
(60–62). In contrast, Goleva et al. showed that IFN-γ reverses 
GC resistance induced in T cells by long-term treatment with 
IL-2 and IL-4 (50).
Various mechanisms leading to GC resistance have been 
proposed. We show here that treatment with IFN-γ and 
PbNK65 extract, in the presence or absence of GCs, affects 
neither GR levels nor GR S211 or S226 phosphorylation in lung 
endothelial cells. GR S211 phosphorylation is associated with 
enhanced GR activity, whereas GR S226 phosphorylation exerts 
inhibitory effects on GR (48, 49, 63). In contrast to our findings, 
several proinflammatory cytokines have been shown to reduce 
GR levels or GR S211 phosphorylation. For example, IL-2 and 
IL-4 impair GR S211 phosphorylation in T  cells (50). TNF 
downregulates the levels of hepatic GR in vivo, whereas TGF-β 
exposure (before challenge with IL-1α) reduces GR levels in 
A549 cells (64, 65). However, TGF-β induced by respiratory 
syncytial virus fails to downregulate GR levels in human airway 
epithelial cells (66). Proteasomal degradation of GR reduces its 
levels and was proposed to cause GC resistance in endothelial 
cells (32, 33).
Impaired GR nuclear translocation represents another way to 
mediate GC resistance in various models. In B cells, treatment 
with IL-4 and IL-15 inhibits GR translocation (31). Similarly, IL-4 
and IL-2 impair GR translocation in T cells (50). Superantigens 
block GR translocation in PBMCs (67). In contrast, GR translo-
cation remains functional in GC resistant HUVECs and lack of 
response to GCs is associated with defects downstream of GR 
translocation (68). This is in line with our data, since GR still 
translocated in the resistant condition with IFN-γ and PbNK65 
extract. Moreover, IFN-γ and PbNK65 extract did not affect 
mRNA levels of FKBP51 (Figure S1 in Supplementary Material), 
which sequesters GR in the cytoplasm and has been implicated 
in GC resistance (69, 70).
FigUre 10 | PbNK65 extract in combination with IFN-γ impairs inhibitory effects of glucocorticoids (GC) on MAPK in lung endothelium. (a) IFN-γ signals through 
IFNGR and activates STAT1 and MAPK signaling. STAT1 homodimer translocates to the nucleus and activates gene transcription. MAPK induce gene expression  
via specific transcription factors (TFs). GC upon entering the cell bind to glucocorticoid receptor (GR) and inhibit activation of JNK and p38 induced by IFN-γ. This 
reduces proinflammatory genes expression. (B) When cells are stimulated with IFN-γ and PbNK65 extract, GC fail to block p38 and JNK activation. Therefore, 
transcription of proinflammatory genes remains unaffected.
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Since STAT1 signaling mediates transcription of a sig-
nificant subset of IFN-γ-induced genes, we investigated the 
effects of GCs on STAT1 activation. In our model, GCs failed 
to affect STAT1 expression and phosphorylation. Conversely, 
GCs suppress STAT1 phosphorylation via SOCS1 induction in 
macrophages activated with TLR-ligands (71). Another study 
showed that GCs inhibit STAT1 expression after long-term 
incubation in PBMCs treated with IFN-γ but fail to affect its 
protein stability (72). In macrophages challenged with type I 
IFN, GCs antagonize STAT1-STAT2-IRF9 (ISGF3) transcrip-
tional complex via depletion of GRIP1/TIF2 (used by ISGF3 
as coactivator) (73). GRIP1/TIF2 mediates anti-inflammatory 
actions of GCs in macrophages via inhibition of cytokine genes 
(74). Furthermore, conditional deletion of GRIP1 in obese 
mice results in macrophage infiltration and inflammation in 
the liver (75).
Here, we also studied the effect of dexamethasone on the MAPK 
signaling pathway—a known target of the anti-inflammatory 
action of GCs. We found that JNK and p38 play an important role 
in the induction of proinflammatory cytokines in lung endothelial 
cells upon stimulation with IFN-γ or IFN-γ and PbNK65 extract. 
Dexamethasone inhibited JNK and p38 phosphorylation upon 
challenge with IFN-γ. However, this inhibitory effect was lost 
when cells were stimulated with IFN-γ and PbNK65 extract. GCs 
have been shown to block MAPK phosphorylation in various 
experimental models. For example, GCs inhibit JNK via pro-
tein–protein interaction in HeLa cells. GR interacts with JNK via 
a hormone-regulated JNK docking site in the GR ligand-binding 
domain and induces disassembly of JNK from mitogen-activated 
protein kinase kinase 7 (MKK7) (54). In macrophages challenged 
with LPS, dexamethasone inhibits p38 but neither ERK nor JNK 
(53). However, dexamethasone blocks JNK phosphorylation in 
HUVECs stimulated with TNF (76). GCs also inhibit JNK, p38 
and ERK phosphorylation in human lung endothelial cells chal-
lenged with TNF, IL-1β, and H2O2 (77).
Numerous studies confirm a highly complex interaction 
between GR and MAPK signaling. GR phosphorylation by p38 
mediates beneficial effects of GCs. For example, GC-induced 
apoptosis in lymphoid cells requires S211 phosphorylation of 
GR by p38 (78). Similarly, p38 activation by LPS in a model 
of acute lung injury enhances anti-inflammatory actions of 
GR (25). In contrast, JNK negatively regulates the activities of 
GR by S226 phosphorylation, resulting in enhanced nuclear 
export and termination of GR signaling (48). MAPK and GR 
interaction might also result in GC resistance. In airway smooth 
muscle cells, p38 phosphorylates GR at S203 acting as a negative 
regulator GR transcriptional activity (79). Inhibition of JNK 
enhances GR binding to GREs in mouse hippocampal cells (80). 
Moreover, JNK activation by cholesterol impairs GR-mediated 
transactivation (81).
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MKP-1 (DUSP1) is an important mediator of GC inhibitory 
actions on MAPK signaling (82, 83). MKP-1 (DUSP1) inhibits 
p38 in macrophages stimulated with TNF and also blocks JNK and 
p38 in macrophages challenged with LPS (53, 84). Furthermore, 
in macrophages from patients with severe asthma, the activity 
of p38 was increased while expression of MKP-1 (DUSP1) was 
reduced (29). MKP-1 (DUSP1) also blocks p38 in endothelial cells 
(76). We observed increased mRNA levels of MKP-1 (DUSP1) 
after stimulation with IFN-γ and PbNK65 compared to IFN-γ 
alone in the presence of dexamethasone. Moreover, we evaluated 
the expression of GILZ upon challenge with IFN-γ and PbNK65 
and dexamethasone but we found no difference when compared 
with IFN-γ alone. GILZ has been suggested to induce MKP-1 
(DUSP1) expression. However, silencing of GILZ in HUVECs 
failed to alter the proinflammatory response to TNF (85, 86).
In conclusion, we here show that PbNK65 extract in combina-
tion with IFN-γ impairs GC-mediated transcriptional inhibition 
of inflammatory chemokines in murine lung endo thelial cells. In 
contrast, lung endothelial cells remain GC sensitive when chal-
lenged with IFN-γ alone. GCs block activation of JNK and p38 
upon challenge with IFN-γ. However, PbNK65 extract interferes 
with the inhibitory actions of GCs on p38 and JNK. This work 
offers an interesting explanation of our previous observation in 
the preclinical model of MA-ARDS, namely that GCs could only 
block the pulmonary inflammation at extremely high dosages 
and were even then not able to downregulate the expression of 
several inflammatory genes in the lungs (9). Our data provide a 
unique view on the regulation of IFN-γ-induced inflammation 
and identify P. berghei NK65 as a novel inducer of GC resistance 
in lung endothelial cells.
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